Bluebird Bio, Inc. (BLUE)

$0.48

-0.01

(-2.24%)▲

Live

Performance

  • $0.48
    $0.50
    $0.48
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.77%

    Upside

    3.77%

    downward going graph
  • $0.45
    $5.53
    $0.48
    downward going graph

    5.65%

    Downside

    52 Weeks Volatility :91.81%

    Upside

    91.32%

    downward going graph

Returns

PeriodBluebird Bio, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-56.95%
3.6%
0.0%
6 Months
-48.53%
10.2%
0.0%
1 Year
-82.96%
19.6%
0.0%
3 Years
-96.32%
16.8%
-23.0%

Highlights

Market Capitalization
94.3M
Book Value
$0.27
Earnings Per Share (EPS)
-2.3
PEG Ratio
0.32
Wall Street Target Price
2.75
Profit Margin
0.0%
Operating Margin TTM
-548.99%
Return On Assets TTM
-36.24%
Return On Equity TTM
-186.7%
Revenue TTM
54.9M
Revenue Per Share TTM
0.36
Quarterly Revenue Growth YOY
133.7%
Gross Profit TTM
-247.2M
EBITDA
-302.1M
Diluted Eps TTM
-2.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.37
EPS Estimate Next Year
-0.65
EPS Estimate Current Quarter
-0.38
EPS Estimate Next Quarter
-0.37

Analyst Recommendation

Buy
    50%Buy
    40%Hold
    10%Sell
Based on 20 Wall street analysts offering stock ratings for Bluebird Bio, Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
8
8
8
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 472.92%

Current $0.48
Target $2.75

Company Financials

FY18Y/Y Change
Revenue
54.6M
↑ 54.06%
Net Income
-555.6M
↑ 65.54%
Net Profit Margin
-1.0K%
↓ 70.6%
FY19Y/Y Change
Revenue
44.7M
↓ 18.15%
Net Income
-789.6M
↑ 42.11%
Net Profit Margin
-1.8K%
↓ 749.47%
FY20Y/Y Change
Revenue
250.7M
↑ 461.25%
Net Income
-618.7M
↓ 21.65%
Net Profit Margin
-246.75%
↑ 1520.74%
FY21Y/Y Change
Revenue
3.7M
↓ 98.54%
Net Income
-562.6M
↓ 9.06%
Net Profit Margin
-15.4K%
↓ 15117.48%
FY22Y/Y Change
Revenue
3.6M
↓ 1.77%
Net Income
-266.6M
↓ 52.62%
Net Profit Margin
-7.4K%
↑ 7953.11%
FY23Y/Y Change
Revenue
29.5M
↑ 720.04%
Net Income
-211.9M
↓ 20.51%
Net Profit Margin
-718.42%
↑ 6692.7%
Q1 FY23Q/Q Change
Revenue
2.4M
↑ 3740.32%
Net Income
34.0M
↑ 5.62%
Net Profit Margin
1.4K%
↓ 50557.32%
Q2 FY23Q/Q Change
Revenue
6.9M
↑ 189.37%
Net Income
-72.9M
↓ 314.16%
Net Profit Margin
-1.1K%
↓ 2487.95%
Q3 FY23Q/Q Change
Revenue
12.4M
↑ 79.85%
Net Income
-71.7M
↓ 1.61%
Net Profit Margin
-578.85%
↑ 479.32%
Q4 FY23Q/Q Change
Revenue
7.8M
↓ 36.78%
Net Income
-88.5M
↑ 23.4%
Net Profit Margin
-1.1K%
↓ 551.02%
Q1 FY24Q/Q Change
Revenue
18.6M
↑ 137.08%
Net Income
-69.8M
↓ 21.14%
Net Profit Margin
-375.84%
↑ 754.03%
Q2 FY24Q/Q Change
Revenue
16.1M
↓ 13.31%
Net Income
-81.4M
↑ 16.6%
Net Profit Margin
-505.52%
↓ 129.68%
FY18Y/Y Change
Total Assets
2.2B
↑ 18.01%
Total Liabilities
357.8M
↑ 29.1%
FY19Y/Y Change
Total Assets
1.7B
↓ 22.98%
Total Liabilities
442.4M
↑ 23.66%
FY20Y/Y Change
Total Assets
1.8B
↑ 3.12%
Total Liabilities
426.2M
↓ 3.67%
FY21Y/Y Change
Total Assets
593.8M
↓ 66.66%
Total Liabilities
219.5M
↓ 48.49%
FY22Y/Y Change
Total Assets
554.9M
↓ 6.55%
Total Liabilities
358.6M
↑ 63.34%
FY23Y/Y Change
Total Assets
619.2M
↑ 11.58%
Total Liabilities
424.6M
↑ 18.43%
Q1 FY23Q/Q Change
Total Assets
692.7M
↑ 24.84%
Total Liabilities
338.0M
↓ 5.73%
Q2 FY23Q/Q Change
Total Assets
663.4M
↓ 4.24%
Total Liabilities
374.4M
↑ 10.76%
Q3 FY23Q/Q Change
Total Assets
613.6M
↓ 7.5%
Total Liabilities
391.1M
↑ 4.46%
Q4 FY23Q/Q Change
Total Assets
619.2M
↑ 0.9%
Total Liabilities
424.6M
↑ 8.58%
Q1 FY24Q/Q Change
Total Assets
631.5M
↑ 1.99%
Total Liabilities
500.4M
↑ 17.85%
Q2 FY24Q/Q Change
Total Assets
545.2M
↓ 13.66%
Total Liabilities
492.2M
↓ 1.64%
FY18Y/Y Change
Operating Cash Flow
-413.4M
↑ 47.36%
Investing Cash Flow
-679.4M
↑ 114.58%
Financing Cash Flow
737.7M
↓ 31.45%
FY19Y/Y Change
Operating Cash Flow
-564.4M
↑ 36.51%
Investing Cash Flow
507.8M
↓ 174.74%
Financing Cash Flow
21.2M
↓ 97.13%
FY20Y/Y Change
Operating Cash Flow
-470.4M
↓ 16.66%
Investing Cash Flow
-84.3M
↓ 116.61%
Financing Cash Flow
546.7M
↑ 2480.43%
FY21Y/Y Change
Operating Cash Flow
-635.6M
↑ 35.14%
Investing Cash Flow
562.6M
↓ 766.97%
Financing Cash Flow
-94.0M
↓ 117.19%
FY22Y/Y Change
Operating Cash Flow
-353.0M
↓ 44.47%
Investing Cash Flow
250.5M
↓ 55.48%
Financing Cash Flow
54.3M
↓ 157.74%
Q1 FY23Q/Q Change
Operating Cash Flow
-86.6M
↑ 53.96%
Investing Cash Flow
82.1M
↓ 20.44%
Financing Cash Flow
130.5M
↓ 113540.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-72.7M
↓ 16.06%
Investing Cash Flow
6.9M
↓ 91.54%
Financing Cash Flow
-445.0K
↓ 100.34%
Q3 FY23Q/Q Change
Operating Cash Flow
-61.8M
↓ 14.96%
Investing Cash Flow
62.1M
↑ 793.92%
Financing Cash Flow
-42.0K
↓ 90.56%

Technicals Summary

Sell

Neutral

Buy

Bluebird Bio, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bluebird Bio, Inc.
Bluebird Bio, Inc.
0.39%
-48.53%
-82.96%
-96.32%
-99.46%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bluebird Bio, Inc.
Bluebird Bio, Inc.
NA
NA
0.32
-1.37
-1.87
-0.36
NA
0.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bluebird Bio, Inc.
Bluebird Bio, Inc.
Buy
$94.3M
-99.46%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Bluebird Bio, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 18.57M → 16.10M (in $), with an average decrease of 13.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -69.80M → -81.39M (in $), with an average decrease of 16.6% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 165.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 141.1%

Institutional Holdings

  • BlackRock Inc

    7.96%

  • Vanguard Group Inc

    5.31%

  • Ameriprise Financial Inc

    3.30%

  • Millennium Management LLC

    2.65%

  • Palo Alto Investors, LLC

    2.39%

  • Geode Capital Management, LLC

    2.33%

Company Information

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.

Organization
Bluebird Bio, Inc.
Employees
375
CEO
Mr. Andrew Obenshain
Industry
Health Technology

Discover More

FAQs